GBA1 and Parkinson disease: This investigational drug (PR001) is composed of a viral vector (adenoassociated virus serotype 9) containing a codon-optimized plasmid encoding a wild-type human GBA gene, proved to be able to increase GCase activity, decrease glycolipid substrate accumulation, and improve motor abnormalities in GBA-PD models in vivo [27,39].